Harmonic Discovery
Multi-targeted therapeutics to treat complex diseases
About Harmonic Discovery
We are a drug discovery company developing a new generation of therapeutics that embrace the complexity of disease. Currently available approaches for creating drugs work on the principle of finding one drug-one protein 'magic bullets'. However, diseases such as cancer and autoimmunity are often the result of several dysregulated proteins across many distinct biological pathways.
We are building a computational-experimental platform to design therapeutics that can target several disease-causing proteins at once. By designing multi-specific drugs, we are able to create therapeutics that are more efficacious and safer than existing medicines.
Company details
Funding
Total raised
$8M
Last stage
Series A
Investors
Founders
Marcel Patek
I am a chemist with training in Medicinal, Organic, Computational, and Peptide chemistry. In my 25+ years in the field, I carried out drug discovery projects involving small molecules and peptides. I worked in environments of startup and global large pharma companies where I led teams and departments in all aspects of early drug discovery. I currently focus on merging experience-based knowledge of molecular optimization with ML/AI systems.
Rayees Rahman
PhD from Icahn School of Medicine at Mount Sinai, where he developed machine learning approaches to characterize the 3D structure of protein kinases and their inhibitors.
LinkedInJason Lee
MD; previously a biotech banker at Deutsche Bank and investor at OrbiMed.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.